supported by the National Natural Science Foundation of China(Nos.82474164,82374124,82073914,82173874,82274185,82305046 and 82304902);the Natural Science Foundation of Jiangsu Province(Nos.BK20230458 and BK20220467);the General Project of the Natural Science Research of Jiangsu Higher Education Institutions(No.23KJB310017);Young Elite Scientists Sponsorship Program by CACM(No.2022-QNRC2-B15).
Developing and identifying effective medications and targets for treating hepatic fibrosis is an urgent priority.Our previous research demonstrated the efficacy of artesunate(ART)in alleviating liver fibrosis by elimi...
This research gained support from the National Key Research and Development Program of China(No.2021YFA1100500);the Major Research Plan of the National Natural Science Foundation of China(No.92159202);the National Natural Science Foundation of China(Nos.32171368 and 81930016);State Key Laboratory for Diagnosis and Treatment of Infectious Diseases(No.zz202310);the Non profit Central Research Institute Fund of Chinese Academy of Medical Sciences(No.2023-PT320-02);the International Science and Technology Cooperation Project of Zhejiang province.
Hepatic ischemia-reperfusion injury(IRI)is an intricate and inevitable physiological event occurred in the liver transplantation(LT)and it is of paramount importance to devise novel and efficient methods to ameliorate...
supported by the National Natural Science Foundation of China(No.82000572,82073914,82173874,82274185);the Natural Science Foundation of Jiangsu Province(No.BK20220467,BK20200840);the Major Project of the Natural Science Research of Jiangsu Higher Education Institutions(No.22KJB310013,19KJA310005);the Joint Project of Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica and Yangtze River Pharmaceutical(No.JKLPSE202005);the Natural Science Foundation of Nanjing University of Chinese Medicine(No.NZY82000572);Nanjing Pharmaceutical Association-Changzhou Fourth Pharmaceutical Hospital Pharmaceutical Research Fund(NO.2021YX030);Postgraduate Research&Practice Innovation Program of Jiangsu Province(No.SJCX22_0792).
Background and Aims:Development of fibrosis in chronic liver disease requires activation of hepatic stellate cells(HSCs)and leads to a poor outcome.Artesunate(Art)is an ester derivative of artemisinin that can induce ...
Diabetes is a metabolic disease characterized by abnormally elevated blood glucose levels.Persistent hyperglycemia leads to diabetic nephropathy,diabetic retinopathy,diabetes with periodontal disease and other diabeti...
Introduction: Artemisinin-based combination therapies are the first-line antimalarial drugs used to treat uncomplicated Plasmodium falciparum malaria in many endemic countries worldwide. In Chad, since the adoption of...
Supported by Education Trust Fund of the University of Uyo(Grant No.ETF 057).
Objective:To evaluate the anti-inflammatory and antipyretic potentials of artesunate in albino mice and Wistar rats respectively.Methods:For the anti-inflammatory activity,artesunate(5 mg/kg)was administered orally ag...
Pharmaceutical counterfeiting is a health scourge responsible for several cases of morbidity and mortality. Counterfeit medicines cause therapeutic failure, emergence of resistance in the treatment of infections. This...
Objective To investigate the effects of artesunate(AS)on septic lung injury in mice and to study the modulation of heme oxygenase-1(HO-1)in lung in order to clarify the mechanism of AS action.Methods Sixty Kunming mal...
research grant(A-059)from All India Institute of Medical Sciences,New Delhi.Artesunate and diclofenac were kind gifts from Arbro Pharmaceuticals Ltd.,New Delhi.
Artesunate, an antimalarial drug, has been shown to inhibit the release of inflammatory mediators in various disease conditions. The present study was carried out to evaluate the anti-edematogenic effect of arte- suna...